Filtered By:
Management: Insurers

This page shows you your search results in order of date.

Order by Relevance | Date

Total 120 results found since Jan 2013.

FDA Approves New Menopause Drug for Hot Flashes
WASHINGTON — U.S. health regulators on Friday approved a new type of drug for women dealing with uncomfortable hot flashes caused by menopause. The Food and Drug Administration approved the once-a-day pill from Astellas Pharma to treat moderate-to-severe symptoms, which can include sweating, flushing and chills. Astellas’ drug, Veozah, uses a new approach, targeting brain connections that help control body temperature. The FDA said the medication will provide “an additional safe and effective treatment option for women,” in a statement. More than 80% of women experience hot flashes during menopause,...
Source: TIME: Health - May 15, 2023 Category: Consumer Health News Authors: Matthew Perrone/AP Tags: Uncategorized Drugs healthscienceclimate wire Source Type: news

Secondary Ischemic Stroke Prevention
AbstractThe health burden of ischemic stroke is high and will continue to increase with an aging population. Recurrent ischemic stroke is increasingly recognized as a major public health concern with potentially debilitating sequelae. Thus, it is imperative to develop and implement effective strategies for stroke prevention. When considering secondary ischemic stroke prevention, it is important to consider the mechanism of the first stroke and the related vascular risk factors. Secondary ischemic stroke prevention typically includes multiple medical and, potentially, surgical treatments, but with the shared goal of reducin...
Source: Neurotherapeutics - March 6, 2023 Category: Neurology Source Type: research

Here ’s an Alternative to Statins for Lowering Cholesterol
Statins have revolutionized heart disease by lowering cholesterol effectively—by up to 50% or more. But anywhere from 7% to 29% of people who take them may be more susceptible to its side effects, which include weakening of muscles and pain, and decide they can’t tolerate them. In a recent study published in JAMA Network Open, for example, researchers at Brigham and Women’s Hospital reported that more than 20% of patients seen at the hospital from 2000 to 2018 who were recommended to take statins refused to take them, and those who refused took three times as long to lower their LDL cholesterol to target ...
Source: TIME: Health - March 4, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthscienceclimate heart health Source Type: news

Effects of Patient Comorbidities and Demographics on Episode-of-Care Costs Following Total Shoulder Arthroplasty
CONCLUSION: Providers should be aware that certain demographic variables and comorbidities (history of stroke, dementia, chronic pulmonary disease, anemia, heart disease, advanced age, and elevated body mass index) are associated with an increase in total costs following primary shoulder arthroplasty. Further study is required to determine whether bundled payment target costs should be adjusted to better compensate for specific comorbidities.LEVEL OF EVIDENCE: Level IV case series.PMID:36749879 | DOI:10.5435/JAAOS-D-22-00450
Source: The Journal of the American Academy of Orthopaedic Surgeons - February 7, 2023 Category: Orthopaedics Authors: Dominic M Farronato Joshua D Pezzulo Alexander J Rondon Sean Porrini Diane McGonigal Charles L Getz Daniel E Davis Source Type: research

FDA Approves Lecanemab, a New Alzheimer ’s Drug
On Jan. 6, the U.S. Food and Drug Administration (FDA) approved a new drug to treat Alzheimer’s disease in its early stages. Lecanemab, which will be available under the name Leqembi, can slow the cognitive decline associated with Alzheimer’s disease by 27%, according to data submitted to the FDA by the drug’s developers, Eisai and Biogen. It’s only the second medication to show any improvement in neurodegeneration, a key criterion in the FDA’s consideration for approval. “For a long time, this is what we have been looking for,” says Dr. Sam Gandy, professor of neurology and psychi...
Source: TIME: Health - January 6, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Drugs healthscienceclimate Source Type: news

Vitamin-K-antagonist phenprocoumon versus direct oral anticoagulants in patients with atrial fibrillation: a real-world analysis of German claims data
Conclusions The small superiority or non-inferiority of DOACs over warfarin seen in the RCTs might not translate into relevant advantages of DOACs over phenprocoumon. To confirm the hypothesis, an RCT with phenprocoumon is needed. Next to the safety and effectiveness assessments other factors might also play a substantial role in the decision on the right OAC for stroke prevention.
Source: BMJ Open - January 2, 2023 Category: General Medicine Authors: Warkentin, L., Klohn, F., Deiters, B., Kühlein, T., Hueber, S. Tags: Open access, Pharmacology and therapeutics Source Type: research

NIH ’s vaunted program for solving puzzling medical cases is running out of money
Ten years ago, an athletic 12-year-old from Affton, Missouri, named Mitchell Herndon began to experience muscle weakness that eventually led to him using a wheelchair. After years of visits to specialists failed to diagnose his neurological symptoms, he enrolled in a National Institutes of Health (NIH)-funded program that studies patients with debilitating mystery diseases. Researchers eventually found an explanation for Mitchell’s condition: a mutated gene that causes certain brain cells to produce an overactive protein that leads to neuron damage. Mitchell died 3 years ago at age 19. Since then, 14 more people hav...
Source: Science of Aging Knowledge Environment - June 27, 2022 Category: Geriatrics Source Type: research

Hospitalisation rate and mortality among people with and without diabetes during the COVID-19 pandemic year 2020
AbstractMost studies reported reduced health care use among people with diabetes during the COVID-19 pandemic. This may be due to restricted medical services or people avoiding health care services because they fear being infected with COVID-19 in health care facilities. The aim of our study was to analyse hospitalisation and mortality in people with and without diabetes in Germany during the COVID-19 pandemic year 2020 compared to 2017 –2019. The data were sourced from a German statutory health insurance company covering 3.2 million people. We estimated age-sex standardised rates of mortality, all-cause hospitalisation,...
Source: European Journal of Epidemiology - June 8, 2022 Category: Epidemiology Source Type: research

Partial upper sternotomy for aortic valve replacement provides similar mid-term outcomes as the full sternotomy
CONCLUSIONS: Upper partial sternotomy can be performed safely for aortic valve replacement, without increased risk of death, stroke or re-admission in 3 years postoperatively.PMID:35572904 | PMC:PMC9096275 | DOI:10.21037/jtd-21-1494
Source: Journal of Thoracic Disease - May 16, 2022 Category: Respiratory Medicine Authors: Jan Hlavicka David Janda Petr Budera Petr Tousek Marek Maly Richard Fojt Hana Linkova Tomas Holubec Petr Kacer Source Type: research